A PROSPECTIVE STUDY OF RAPID CORTICOSTEROID ELIMINATION IN SIMULTANEOUS PANCREAS-KIDNEY TRANSPLANTATION: Comparison of Two Maintenance Immunosuppression Protocols: Tacrolimus/Mycophenolate Mofetil Versus Tacrolimus/Sirolimus1

Background. We examined the feasibility of rapid corticosteroid elimination in simultaneous pancreas kidney transplantation. Methods. Forty consecutive simultaneous pancreas-kidney (SPK) transplant recipients were enrolled in a prospective study in which antithymocyte globulin induction and 6 days of corticosteroids were administered along with tacrolimus and MMF (n=20) or tacrolimus and sirolimus (n=20). Mean±SD follow-up for recipients receiving tacrolimus/MMF and tacrolimus/sirolimus were 12.7±3.9 and 13.4±2.9 months, respectively. Patient and graft survival, and rejection rates were compared to an historical control group (n=86; mean follow-up 41.5±15.4 months) of SPK recipients that received induction and tacrolimus, MMF, and corticosteroids. Results. Demographic characteristics of recipient and donor variables were similar among all groups. The 1-year actuarial patient, kidney, and pancreas survival rates in the 40 SPK transplant recipients with rapid corticosteroid elimination were 100, 100, and 100%, respectively. In the historical control group the 1-year actual patient, kidney, and pancreas survival rates were 96.5, 93.0, and 91.9%, respectively. The 1-year rejection-free survival rate recipients in the rapid steroid elimination group collectively was 97.5 vs 80.2% in the historical control group (P =0.034). At 6 and 12 months posttransplant the serum creatinine values remained stable in all groups. Conclusions. We conclude that chronic corticosteroid exposure is not required in SPK transplant recipients receiving antithymocyte globulin induction and maintenance immuno-suppression consisting of either tacrolimus and mycophenolate mofetil or tacrolimus and sirolimus.

[1]  M. Abecassis,et al.  RISK FACTORS AND IMPACT OF CYTOMEGALOVIRUS DISEASE IN SIMULTANEOUS PANCREAS-KIDNEY TRANSPLANTATION , 2001, Transplantation.

[2]  D. Dunn,et al.  Rapid Discontinuation of Steroids in Living Donor Kidney Transplantation: A Pilot Study , 2001, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[3]  S. Birkeland.  STEROID-FREE IMMUNOSUPPRESSION IN RENAL TRANSPLANTATION: A LONG-TERM FOLLOW-UP OF 100 CONSECUTIVE PATIENTS , 2001, Transplantation.

[4]  D. Dunn,et al.  Lessons Learned From More Than 1,000 Pancreas Transplants at a Single Institution , 2001, Annals of surgery.

[5]  R. Wolfe,et al.  THE IMPACT OF SIMULTANEOUS PANCREAS-KIDNEY TRANSPLANTATION ON LONG-TERM PATIENT SURVIVAL1 , 2001, Transplantation.

[6]  M. Abecassis,et al.  Simultaneous pancreas-kidney transplantation in the mycophenolate mofetil/tacrolimus era: evolution from induction therapy with bladder drainage to noninduction therapy with enteric drainage. , 2000, Surgery.

[7]  J. Bolinder,et al.  Combined pancreas and kidney transplantation improves survival in patients with end‐stage diabetic nephropathy , 2000, Clinical transplantation.

[8]  J. Soulillou,et al.  Low incidence of kidney rejection after simultaneous kidney-pancreas transplantation after antithymocyte globulin induction and in the absence of corticosteroids: results of a prospective pilot study in 28 consecutive cases. , 2000, Transplantation.

[9]  F. Reinholt,et al.  Area under the serum creatinine time-curve is a strong predictor of chronic renal allograft rejection. , 2000, Transplantation.

[10]  J. Fung,et al.  Results of pancreas transplantation after steroid withdrawal under tacrolimus immunosuppression. , 2000, Transplantation.

[11]  D. Stablein,et al.  Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil--a prospective randomized study. Steroid Withdrawal Study Group. , 1999, Transplantation.

[12]  M. Rieder,et al.  Pretreatment with Glucocorticoids Enhances T-Cell Effector Function: Possible Implication for Immune Rebound Accompanying Glucocorticoid Withdrawal , 1999, Cell transplantation.

[13]  D. Dunn,et al.  Decreased acute rejection in kidney transplant recipients is associated with decreased chronic rejection. , 1999, Annals of surgery.

[14]  J. Fung,et al.  Simultaneous administration of adjuvant donor bone marrow in pancreas transplant recipients. , 1999, Annals of surgery.

[15]  J Hornberger,et al.  Incidence and long-term cost of steroid-related side effects after renal transplantation. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[16]  D. Dunlop,et al.  Increased Risk of Fracture in Patients Receiving Solid Organ Transplants , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[17]  M. Abecassis,et al.  Mycophenolate mofetil and tacrolimus as primary maintenance immunosuppression in simultaneous pancreas-kidney transplantation: initial experience in 50 consecutive cases. , 1999, Transplantation.

[18]  R. Stratta.  Review of immunosuppressive usage in pancreas transplantation , 1999, Clinical transplantation.

[19]  S. Knechtle,et al.  Experience with 500 simultaneous pancreas-kidney transplants. , 1998, Annals of surgery.

[20]  R. Stratta,et al.  Simultaneous kidney-pancreas transplantation without antilymphocyte induction. , 1998, Transplantation.

[21]  E. Woodle,et al.  Analysis of fracture prevalence in kidney-pancreas allograft recipients. , 1998, Journal of the American Society of Nephrology : JASN.

[22]  Joshua Miller,et al.  A Comparison Of Tacrolimus (fk506) And Cyclosporine For Immunosuppression After Cadaveric Renal Transplantation1 , 1997 .

[23]  Serdar Yilmaz,et al.  Chronic renal allograft rejection can be predicted by area under the serum creatinine versus time curve (AUCCr). , 1995, Kidney international.

[24]  M. Henry,et al.  The frequency of rejection episodes after combined kidney-pancreas transplant--the impact on graft survival. , 1994, Transplantation.

[25]  Sinclair Nr.  Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts. The Canadian Multicentre Transplant Study Group. , 1992 .

[26]  T. Strom,et al.  Abrogation of glucocorticoid-mediated inhibition of T cell proliferation by the synergistic action of IL-1, IL-6, and IFN-gamma. , 1991, Journal of immunology.

[27]  D. Hricik,et al.  A prospective randomized trial of prednisone versus no prednisone maintenance therapy in cyclosporine-treated and azathioprine-treated renal transplant patients. , 1990, Transplantation.

[28]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[29]  A. Monaco,et al.  Current thinking on chronic renal allograft rejection: issues, concerns, and recommendations from a 1997 roundtable discussion. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[30]  P. Stock,et al.  Simultaneous pancreas-kidney transplantation: an overview of indications, complications, and outcomes. , 1999, The Western journal of medicine.

[31]  A. Matas,et al.  Steroid-related complications in the cyclosporine era. , 1994, Clinical transplantation.